The emergence of PD-1/PD-L1 immune checkpoint blockade (ICB) targeting the programmed cell death-1 (PD-1) and the programmed cell death-ligand 1 (PD-L1) pathway has revolutionized treatments for NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.